Common features between neoplastic and preneoplastic lesions of the biliary tract and the pancreas by Zaccari, P et al.
W J G World Journal ofGastroenterology
Submit a Manuscript: https://www.f6publishing.com World J Gastroenterol  2019 August 21; 25(31): 4343-4359
DOI: 10.3748/wjg.v25.i31.4343 ISSN 1007-9327 (print) ISSN 2219-2840 (online)
REVIEW
Common features between neoplastic and preneoplastic lesions of
the biliary tract and the pancreas
Piera Zaccari, Vincenzo Cardinale, Carola Severi, Federica Pedica, Guido Carpino, Eugenio Gaudio,
Claudio Doglioni, Maria Chiara Petrone, Domenico Alvaro, Paolo Giorgio Arcidiacono, Gabriele Capurso
ORCID number: Piera Zaccari
(0000-0002-4041-5601); Vincenzo
Cardinale (0000-0003-0234-3341);
Carola Severi (0000-0001-9249-1318);
Federica Pedica
(0000-0003-0168-4718); Guido
Carpino (0000-0001-8570-2519);
Eugenio Gaudio
(0000-0001-6180-3091); Claudio
Doglioni (0000-0002-4969-5216);
Maria Chiara Petrone
(0000-0002-1045-209X); Domenico
Alvaro (0000-0003-3771-9644); Paolo
Giorgio Arcidiacono
(0000-0001-6692-7720); Gabriele
Capurso (0000-0002-0019-8753).
Author contributions: Zaccari P
performed literature search and
drafted the manuscript; Cardinale
V, Severi C, Petrone MC, Alvaro D,
Arcidiacono PG and Capurso G
critically revised the manuscript;
Alvaro D, Arcidiacono PG and
Capurso G provided scientific
guidance; Pedica F, Doglioni C and
Capurso G examined pathology
samples and provided appropriate
figures; all authors revised and
approved the final version of this
article.
Supported by Associazione Italiana
Ricerca sul Cancro, Italy, No.
AIRC: IG 17177 to Capurso G.
Conflict-of-interest statement: No
potential conflicts of interest.
Open-Access: This article is an
open-access article which was
selected by an in-house editor and
fully peer-reviewed by external
reviewers. It is distributed in
accordance with the Creative
Commons Attribution Non
Commercial (CC BY-NC 4.0)
Piera Zaccari, Carola Severi, Department of Internal Medicine and Medical Specialties,
Gastroenterology Unit, Sapienza University of Rome, Rome 00161, Italy
Vincenzo Cardinale, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza
University of Rome, 00161 Rome, Italy
Federica Pedica, Claudio Doglioni, Pathology Department, Pancreas Translational and Clinical
Research Center, San Raffaele Scientific Institute IRCCS, Milan 20132, Italy
Guido Carpino, Department of Movement, Human and Health Sciences, Division of Health
Sciences, University of Rome "Foro Italico", Rome 00161, Italy
Eugenio Gaudio, Department of Anatomical, Histological, Forensic Medicine and Orthopedics
Sciences, Division of Human Anatomy, Sapienza University of Rome, Rome 00161, Italy
Maria Chiara Petrone, Paolo Giorgio Arcidiacono, Gabriele Capurso, PancreatoBiliary Endoscopy
and EUS Division, Pancreas Translational and Clinical Research Center, San Raffaele
Scientific Institute IRCCS, Milan 20132, Italy
Domenico Alvaro, Department of Translational and Precision Medicine, Sapienza University of
Rome, Rome 00161, Italy
Corresponding author: Paolo Giorgio Arcidiacono, MD, Chief Doctor, Director of Unit,
Pancreato-Biliary Endoscopy and Endosonography Division, Pancreas Translational and
Clinical Research Centre, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, Milan
20132, Italy. arcidiacono.paologiorgio@hsr.it.
Telephone: +39-02-26435607
Fax: +39-02-26435607
Abstract
the bile duct system and pancreas show many similarities due to their anatomical
proximity and common embryological origin. Consequently, preneoplastic and
neoplastic lesions of the bile duct and pancreas share analogies in terms of
molecular, histological and pathophysiological features. Intraepithelial
neoplasms are reported in biliary tract, as biliary intraepithelial neoplasm (BilIN),
and in pancreas, as pancreatic intraepithelial neoplasm (PanIN). Both can evolve
to invasive carcinomas, respectively cholangiocarcinoma (CCA) and pancreatic
ductal adenocarcinoma (PDAC). Intraductal papillary neoplasms arise in biliary
tract and pancreas. Intraductal papillary neoplasm of the biliary tract (IPNB)
share common histologic and phenotypic features such as pancreatobiliary,
gastric, intestinal and oncocytic types, and biological behavior with the
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pancreatic counterpart, the intraductal papillary mucinous neoplasm of the
pancreas (IPMN). All these neoplastic lesions exhibit similar
immunohistochemical phenotypes, suggesting a common carcinogenic process.
Indeed, CCA and PDAC display similar clinic-pathological features as growth
pattern, poor response to conventional chemotherapy and radiotherapy and, as a
consequence, an unfavorable prognosis. The objective of this review is to discuss
similarities and differences between the neoplastic lesions of the pancreas and
biliary tract with potential implications on a common origin from similar
stem/progenitor cells.
Key words: Biliary; Pancreatic; Progenitors; Preneoplastic; Common; Tumor
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: The carcinogenesis process of the biliary tract and the pancreas has common
histological, biologic and molecular characteristics possibly due to similar
stem/progenitors origin. Such findings could set the base for studies aimed at identifying
novel strategies for prevention, surveillance and treatment of these deadly diseases.
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INTRODUCTION
The biliary  tract  and the  pancreas  share  a  common embryologic  origin[1].  In  the
primitive duodenum, the bilio-pancreatic progenitor differentiates in distinct lineages
driven by specific transcription factors such as Hes1 in the case of the hepatobiliary
fate, or Pdx1/Ngn3/MafA in the case of the pancreatic fate[2]. Stem/progenitors for
biliary tree and pancreas exist at early stages of human development and both derive
from  the  definitive  anterior  endoderm  forming  foregut [ 3 ].  During  human
development, the hepatic diverticulum emerges from the foregut[4]. While the cranial
part of the diverticulum forms the liver and the intrahepatic bile ducts (IHBDs), the
extrahepatic bile ducts (EHBDs) and ventral pancreas arise from its caudal part[5]. The
large IHBDs and the EHBDs share the presence of glands in their duct walls, which
are named peribiliary glands (PBGs)[6]. PBGs are more commonly located at branching
points of the biliary tree and at the hepatopancreatic ampulla. It has been clearly
demonstrated that specialized glands of the biliopancreatic tract contain niches of
stem/progenitors  cells  that  could  have  an  important  role  in  the  carcinogenesis
process, when they are activated in response to chronic stimuli[7]. Niches of biliary tree
stem cells (BTSCs) are located at the bottom of PBGs, near the fibromuscular layer;
these cells express markers of stem/progenitors’ cells of endodermal origin and can
proliferate and self-renew[8].  BTSCs are able to differentiate in vitro and in vivo,  in
experimental  models  of  liver  diseases  or  streptozotocin-induced  diabetes,  into
cholangiocytes and, hepatocytes, or pancreatic islets[9].  Interestingly multipotency
property and the capability to respond to hyperglycemia in vivo are suggested by data
obtained in animal models of diabetes and in humans affected by type II diabetes
mellitus,  where  PBGs  undergo  proliferation  and  expansion  in  response  to
hyperglycemia differentiating toward insulin-producing cells[10]. These data open to
the exciting hypothesis that the PBG niche commitment to endocrine pancreatic fate
may contribute to the homeostatic pancreatic islet regeneration response observed in
diabetes[7].  Studies  of  human  anatomy  support  the  hypothesis  that  BTSCs  are
organized in a proximal-to-distal  axis,  in which the hepatopancreatic  ampulla is
considered the proximal site where the most primitive stem biliary tree and pancreas
reside. In fact, pancreatic stem cell traits persist in the adult biliary tree, especially at
the ampullary region[11].
In the pancreas, pancreatic ductal glands (PDGs) containing pancreatic committed
progenitors are observed within the walls of larger pancreatic ducts (Figure 1). PDGs
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are more numerous in the main pancreatic duct at the head of the pancreas than in the
tail and in larger interlobular ducts, where PDGs progressively reduce and finally,
disappear in interlobular ducts with a diameter < 300 μm[12].  PDGs are therefore
considered the pancreatic  counterpart  of  PBGs[13],  they are most abundant at  the
hepatopancreatic ampulla and their distribution along larger pancreatic ducts shows
similarities with the distribution of PBGs in the biliary tree[7,12] (Figure 1).
To sum up, on the basis of the progenitor segregation, multiple stem cell niches
persist in specific anatomical locations within adult human organs: (1) BTSCs in PBGs
along EHBD and large IHBDs; and (2) Pancreatic stem cells that appear confined to
the  biliary  tree,  particularly  the  hepatopancreatic  common  duct,  while  their
descendants,  committed  progenitors,  are  observed within  the  pancreatic  ductal
system in PDGs[11] (Figure 1). These stem/progenitor cell niches may contribute to
repair pervasive, chronic injuries, whereas the replication of mature parenchymal cells
ensures physiological turnover and restoration of parenchyma after minor injuries.
The above mentioned similarities in the embryological and histological features
between  the  biliary  tree  and  the  pancreas  are  reflected  in  the  clinic-pathologic
similarities of several diseases affecting these two organs, such as their involvement in
IgG4  related-disease,  preneoplastic  lesions  and  cancers [14 -16 ].  Accordingly,
cholangiocarcinoma (CCA) and pancreatic ductal adenocarcinoma (PDAC) seem to
share molecular pathways and cells of origin as recently suggested by the results of
the wide molecular characterization of determined clinical-pathological classified
malignancies conducted in The Cancer Genome Atlas results[17,18]. Interestingly, there
is also evidence that common risk factors, such as obesity and diabetes mellitus, are
associated with both CCA[19] and PDAC[20].
The present review article will  discuss available evidence concerning common
features between neoplastic  and preneoplastic  lesions of  the biliary tree and the
pancreas.
INTRAEPITHELIAL NEOPLASMS OF THE BILIARY TRACT
AND PANCREAS
One of the most relevant malignant precursors of biliary tract cancers is represented
by the biliary intraepithelial neoplasm (BilIN), a microscopic not macroscopically
identifiable lesion, with a micropapillary, pseudopapillary or flat growth pattern,
involved in the process of multistep cholangiocarcinogenesis[21]. BilIN represents the
biliary counterpart  of  pancreatic  intraepithelial  neoplasia  (PanIN)[13,22].  BilIN are
usually encountered in the epithelium lining the EHBDs and large IHBDs and may
also be found in the gallbladder[23,24]. Furthermore, these preneoplastic lesions have
been  identified  and  characterized  in  chronic  hepatobiliary  diseases  such  as
hepatolithiasis, primary sclerosing cholangitis (PSC) and choledocal cyst, which are
associated  with  an  increased risk  of  developing CCA,  particularly  the  perihilar
CCA[23-27].  BilINs  are  also  observed  by  histological  examination  in  the  biliary
epithelium close to invasive biliary tract cancers[28]. Based on the degree of cellular and
architectural atypia, BilINs have been classified into three categories: BilIN-1 (low
grade dysplasia) showing the mildest changes compared to non-neoplastic epithelium
of the bile ducts; BilIN-2 (intermediate grade dysplasia) with increased nuclear atypia
and focal anomalies of cellular polarity as compared to BilIN-1; BilIN-3 (high grade
dysplasia or carcinoma in situ), which are usually identified in proximity of CCA
areas[29] (Figure 2).
Regarding the expression of cell cycle-related molecules, it has been shown that p21
and cyclin D1 are progressively upregulated with the increase of BilIN grades, while
the  expression  of  the  tumor  suppressor  gene  SMAD4  gets  down-regulated.
Interestingly, a significant upregulation of p53 is observed in BilIN-3 and invasive
CCA in contrast to BilIN-1 and BilIN-2, suggesting an important role of p53 in the
acquisition of invasive growth capacity in the final step of transformation into CCA.
Importantly,  p21,  cyclin  D1  and  p53  are  not  expressed  in  the  non-neoplastic
epithelium of bile ducts[30].
The expression pattern of cytoplasmic and luminal surface mucins is also altered
during the increase in the degree of BilIN, with some evidences showing that the
expression of MUC1 increases with the increase of BilIN grades, while the expression
of  MUC5AC  is  high  in  all  BilIN  grades[31].  Interestingly,  BilIN  are  sporadically
associated  with  intestinal  metaplasia  that  could  explained  the  focal  immu-
nohistochemical  expression  of  MUC2,  whereas  this  mucin  is  not  identified  in
PanINs[22]. Moreover, the immunohistochemical expression of S100 proteins has been
found to be increased in BilIN compared to the non-neoplastic epithelium of bile
ducts.  In particular,  S100P is  specifically expressed in BilIN-3 and invasive CCA
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Figure 1
Figure 1  Common and Distinctive Features of peribiliary and pancreatic ductal glands. The peribiliary glands are tubule-alveolar glands present within the walls
of larger biliary ducts, more commonly located at branching points of the biliary tree, in particular at the hepatopancreatic region. The pancreatic ductal glands
containing pancreatic committed progenitors are observed within the walls of larger pancreatic ducts. PBGs: Peribiliary glands; PDGs: Pancreatic ductal glands.
rather than in BilIN-1/-2, suggesting an involvement of S100P in the late phases of the
multistep cholangiocarcinogenesis process[32].
The demonstration that PBGs are stem cell niches of large IHBDs and EHBDs have
increased the attention on these structures in the neoplastic transformation of the bile
ducts. BilIN are also reported in PBGs and are graded as BilIN-1/-2/-3 as well[33].
Several studies suggested a role of PBGs in the response to chronic inflammatory
stimuli of bile ducts such as those occurring in PSC, through a process leading to the
occurrence of dysplastic lesions and consequently CCA development[34]. BilIN in PBGs
also  showed  a  strong  immunoreactivity  to  S100P,  and  carcinoembryonic  and
carbohydrate antigen 19-9[35].
The  pancreatic  counterpart  of  intraepithelial  neoplasm  of  the  biliary  tract  is
represented by PanINs, defined as a microscopic flat or micropapillary noninvasive
lesions,  usually  inferior  to  5  mm,  and  considered  the  most  common  malignant
precursors of PDAC, with a lower proportion of cases originating from intraductal
papillary  mucinous  neoplasms  of  the  pancreas  (IPMNs)  and  mucinous  cystic
neoplasms (MCNs)[36]. PanINs have been classified, according to the degree of cellular
and architectural atypia, into low grade (previously classified as PanIN-1 and PanIN-
2) with mild-moderate cytological atypia and basally located nuclei, and high grade
(previously classified PanIN-3) with severe cytological atypia, loss of polarity and
mitoses[37,38]. The findings of loss of nuclear polarity, increased nucleus-to-cytoplasm
ratio, nuclear hyperchromasia, and architectural atypia are basically similar between
BilINs and PanINs[39].
As for the expression of cell cycle-related molecules, the immunohistochemical
expression of cyclin D1, p21 and p53 which is absent in nonneoplastic pancreatic
ductal epithelium, has been reported in high grade PanIN compared to low grade
PanINs, as well as in BilINs[22]. The loss of SMAD4 expression which is a typical late
event in pancreatic carcinogenesis has been demonstrated in high-grade but not in
low-grade PanINs[40].  As far as the expression of mucins is  concerned, except for
MUC2 expression, that is almost absent in PanINs, a similar expression pattern is
found in BilINs and PanINs. MUC1 is progressively over-expressed in the process
from PanIN to PDAC, while MUC5AC is also expressed in PanIN, especially when
occurring in PDAC compared to normal pancreata[22,41]. The finding of upregulated
expression  of  the  above  mentioned  mucins  associated  to  higher  PanIN  grades
supports their role in the early phases of pancreatic carcinogenesis for which they
might be useful biomarkers. The expression of S100P is also increased in high grade
PanINs  and  PDAC  compared  to  the  low  grade  PanINs[42,43].  The  most  common
mutated  gene  found in  in  over  90% of  PanINs  is  Kras,  especially  in  the  lowest
grades[44].  Mutated  Kras  is  considered  the  initiating  genetic  event  in  PDAC
development  but  it  cannot  alone explain the  progression to  invasive  carcinoma.
Hedgehog  (HH)  signaling  pathway,  crucial  during  embryonic  pancreatic
development and stem cell regulation[45], resulted aberrantly activated both in PanINs
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Figure 2
Figure 2  Common and distinctive features of pancreatic intraepithelial neoplasias and biliary intraepithelial neoplasms. A: Pancreatic intraepithelial
neoplasia, high grade (PanIN-3, 10 ×) sorrounded by infiltrating adenocarcinoma. B: Biliary intraepithelial neoplasia, high grade (BilIN-3, 10 ×) with nearby infiltrating
adenocarcinoma Both lesions are microscopic precancerous lesions of pancreas (A) and biliary tree (B), not identifiable by radiological imaging.
and in invasive carcinoma[46,47]. Sonic Hedgehog (SHH) is one of the three protein of
the Hh signaling pathway family. Overexpression of SHH is reported in PanINs and
PDAC but not in normal pancreas, many studies showed a synergic crosstalk between
mutated Kras and activation of SHH in the early development of cancer[48].  In the
biliary counterpart, Kras mutations are reported in about 30% of cases of BilINs, thus
less  frequently  compared  to  PanINs  but,  similarly  to  what  is  reported  in  the
pancreatic counterpart, they occurr from the lowest grades during the progression to
CCA[49]. Regarding the role of HH signaling pathway, studies revealed that Gli1, a
transcriptional activator target of HH pathway, when overexpressed is associated
with tumor invasion and metastasis in iCCA[50].
Similarly, to what has been reported regarding the activation of PBGs in disorders
associated with increased risk of carcinogenesis in the biliary tract, within in pancreas,
specialized PDGs, containing pancreatic  committed progenitors,  are activated in
response to longstanding stimuli such as in chronic pancreatitis[51]. The upregulation
of  MUC-6  and  a  de-novo  expression  of  MUC5AC  has  been  reported  in  PDGs,
supporting the hypothesis that these niches might contribute to mucinous metaplasia
with features of PanIN-like lesions, and to the development of dysplastic pancreatic
lesions[52].
In  conclusion,  there  is  solid  evidence  that  BilINs  and  PanINs  share  common
histological  and  immunohistochemical  features  and  similar  molecular  changes
associated with the multistep carcinogenetic process respectively of CCA and PDAC.
INTRADUCTAL PAPILLARY NEOPLASMS OF PANCREATO-
BILIARY SYSTEMS
Intraductal papillary neoplasms of the biliary tract (IPNBs) are a rare variant of bile
duct tumors that are considered the biliary counterpart of pancreatic IPMNs. Both
arise  within  the  ductal  system and show a  predominantly  intraductal  papillary
growth pattern[53]. IPNBs can arise along all the biliary tree from both EHBDs and
IHBDs and represent an alternative carcinogenesis pathway, distinct from BilIN[54,55].
Histologically, IPNBs show papillary proliferation of neoplastic biliary epithelium
with delicate fibrovascular cores associated with luminal dilatation of the affected bile
ducts, sometimes with mucin hypersecretion and, occasionally with prominent cystic
changes[56].  The neoplastic epithelium of IPNBs is characterized by a spectrum of
cytologic and architectural atypia. Based on these features, IPNBs are classified into
low  or  intermediate  grade  intraepithelial  neoplasia,  high  grade  intraepithelial
neoplasia  and  IPNB  with  invasive  carcinoma [57,58]  (Figure  3).  Regarding  the
immunophenotype  and  the  histology,  IPNBs  are  classified  into  four  epithelial
subtypes:  (1) Pancreatobiliary;  (2) Gastric;  (3) Intestinal;  and (4) Oncocytic types,
according to the immunophenotype classification of IPMNs[59,60]. The pancreatobiliary
subtype is the most common subtype of IPNB followed by the intestinal, gastric and
oncocytic ones[61]. Immunohistochemically, mucin core proteins are associated with
the epithelial subtypes in IPNB, as well as in IPMNs[62]. MUC-1 has been reported to
be expressed mainly in the pancreatobiliary subtype but not in the others,  while
MUC-2 is expressed in the intestinal subtype and MUC5AC in all subtypes including
the oncocytic one, which also shows a focal expression of MUC-1 and/or MUC-2[63].
For  this  reason,  the  oncocytic  form  could  be  considered  a  variant  of  the
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pancreatobiliary  subtype.  While  mucin  hypersecretion is  a  typical  and frequent
feature of IPMNs, its presence in IPNBs is more frequently reported in the gastric and
intestinal subtypes rather than in the pancreatobiliary one[64].
The  expression  of  several  cytokeratins  has  also  been  related  to  the  different
subtypes.  Particularly,  CK-20 expression has  been associated with the intestinal
subtype, whereas CK-7 with the gastric subtype[65].
Several  studies  suggested a  role  of  PBGs in  the development  of  IPNBs[33,66].  A
possible hint toward the origin of IPNBs from PBGs is represented by the high level of
expression of another gastric mucin MUC6, which is not normally expressed in the
biliary epithelium, both in PBGs and IPNBs, supporting the hypothesis of PBGs-
derived IPNBs[67].
As far as regards the pancreas, IPMNs are defined as a grossly visible noninvasive
epithelial neoplasm constituted of mucin-producing cells which could arise from the
main  pancreatic  duct  (IPMN-MD)  and/or  from the  branch  ducts  (IPMN-BD)[68].
Microscopically, IPMNs show a papillary proliferation with delicate fibrovascular
cores[69]. Based on cytoarchitectural atypia, IPMNs are classified according to WHO
classification into: (1) Low grade dysplasia characterized by regular tall columnar cells
with no or only minor signs of atypia; (2) Intermediate grade dysplasia with moderate
cytological atypia, such as hyperchromasia and enlarged nuclei; and (3) High grade
dysplasia, which displays marked nuclear atypia with loss of polarity, enlarged and
pleomorphic nuclei[57,70].
IPMNs are extremely common incidentally diagnosed lesions with a prevalence of
some 7% in the healthy population[71], the majority being represented by IPMN-BD,
that are associated with a relatively low risk of neoplastic transformation estimated in
0-7% per year[72]. In contrast, IPNBs are rare lesions, mostly reported in far eastern
nations like Taiwan, Japan, and Korea where chronic diseases such as hepatolithiasis
and clonorchiasis are endemic[62,73]. The most common epithelial subtype of IPMN-BD
is represented by the gastric subtype, which is MUC-1 negative, MUC5AC positive,
and CK20 negative, meanwhile the most common epithelial subtypes reported in
IPMN-MD are the intestinal and the pancreatobiliary subtypes, which are respectively
MUC-2/MUC5AC positive and MUC-1 negative, and MUC-1/MUC5AC positive and
MUC-2 negative[74].
Several studies reported that the pattern of expression of mucins is related with two
distinct types of tumor progression that might occur in IPMNs: the MUC1positive
pathway leading to tubular adenocarcinoma and the MUC2positive pathway which
evolves into mucinous adenocarcinoma[75]. There is some evidence suggesting that the
pancreatobiliary subtype is  strongly associated with invasive tubular  carcinoma
which holds the poorest prognosis due to the more advanced stage at presentation
and  high  recurrence  after  curative  resection[76],  and  that  MUC-1  expression  is
associated with a shorter overall survival, similarly to what reported in IPNBs[56,77,78].
Similarly to what has been reported for the possible origin of IPNBs from PBGs, it
has been hypothesized that PDGs might have a central role in the development of
IPMNs, as suggested by the observed high levels of expression of Trefoil factor family
2 (TFF2) in IPMNs, a protein expressed also by PDGs[79]. As mentioned above, the
expression patterns of mucin core proteins and cytokeratins of IPMNs, especially the
main duct ones, resembles that observed in IPNBs[80].
Beyond all the similarities, there are also several differences between IPMNs and
IPNBs: (1) Mucin production is observed in almost all cases of IPMNs whereas it is
reported in only one third of IPNB cases;  (2) The gastric subtype of IPNB is rare
compared to what observed for IPMNs and; (3) The expression of CK20 is far more
common  in  IPNBs  compared  with  IPMNs[80,81].  In  conclusion,  while  there  are
evidences suggesting that IPNBs and IPMNs of the MD share common histologic and
phenotypic  features  associated  with  a  relatively  high  risk  of  malignant
transformation, supporting the case of an almost identical entity, on the contrary,
most  IPMN-BDs  have  a  different  molecular  profile  and  biological  and  clinical
behavior.
CHOLANGIOCARCINOMA AND PANCREATIC DUCTAL
ADENOCARCINOMA
As discussed above, both microscopic (PanINs and BilINs) and macroscopic (IPMNs
and IPNBs)  precursor  lesions  of  pancreatic  ductal  adenocarcinoma (PDAC) and
cholangiocarcinoma (CCA) share many common aspects, which may be explained by
the  described  common  embryologic  development  of  the  biliary  tract  and  the
pancreatic duct system.
CCA is  the  second most  common primary liver  tumors[82]  and its  incidence is
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Figure 3
Figure 3  Common and distinctive features of pancreatic and biliary intraductal papillary mucinous neoplasms. Low power view of intraductal papillary
mucinous neoplasm of the pancreas (A) with oncocytic aspects (B), causing evident dilatation of the Wirsung duct which was detected radiologically as a macroscopic
lesion. Low power view of intraductal papillary neoplasm of the bile duct (C) characterized by a polypoid growth inside the common hepatic duct, composed of multiple
papillary projections with a fibrovascular stroma and covered by oncocytic cells (D). In the upper left part of panel D at higher magnification, the transition between the
normal bile duct epithelium and the papillary neoplastic proliferation is evident.
increasing worldwide[83].  CCA constitutes a heterogeneous group of malignancies
arising within the biliary tree[84,85], and based on its anatomical location, it is currently
classified into intrahepatic  CCA (iCCA),  perihilar  CCA (pCCA),  and distal  CCA
(dCCA)[86-88]. While, the pCCA and dCCA are typically conventional mucin-producing
adenocarcinomas  or  papillary  tumors,  iCCA  may  present  histologically  as
conventional adenocarcinoma, cholangiolocarcinoma (CLC), or as rare histological
variants[88]. Recently it appeared that the conventional iCCA comprise two separate
histological subtypes: The small bile duct-type iCCA, described as nodular invasive
peripheral tubular or acinar adenocarcinoma with no or minimal mucin production,
and the large bile duct-type iCCA characterized by the mucinous production and by
the involvement of the large IHBDs[88]. Interestingly the large bile duct-type iCCA, but
not small bile duct-type iCCA, share similar characteristics with pCCA and PDAC[89].
Based on embryology, iCCA subtypes reflect the different cells of origin. In fact,
several studies reported that the small bile duct-type iCCA could emerge from the
hepatic/stem progenitor cells located at the level of canals of Hering or ductules, in
opposition to the p/dCCA and large bile duct-type iCCA which could originate from
cholangiocytes or PBG-cells[90,91]. A large body of evidences indicates that large bile
duct-type  iCCAs  and  p/dCCA  originate  from  PBGs[92]  on  the  basis  of:  (1)  The
anatomical  location of PBGs is  similar to those of  large bile duct-type iCCA and
p/dCCA  origin  in  the  biliary  tree;  (2)  PBGs  activation  can  lead  to  mucinous
metaplasia  favoring  the  occurrence  of  preneoplastic  lesions;  and  (3)  Cells  with
stem/progenitor markers exclusively located at the bottoms of PBGs, are detected in
cancer stem cells identified in large bile duct-type iCCAs and p/dCCA[93].
PDAC is the one of leading causes of cancer mortality in developed countries, and
one of the most lethal malignant neoplasms across the world[94,95]. PDAC represents
nearly 90% of all pancreatic neoplasms[96] and can be considered as the pancreatic
counterpart of  p/dCCA. Based on these premises,  we will  focus on the common
aspects  between  p/dCCA  and  PDAC.  In  fact,  these  malignancies  both  appear
macroscopically as firm grayish infiltrating masses with a nodular-sclerosing pattern
of growth; histologically, both can produce mucin, are generally well differentiated
tubular adenocarcinomas sometimes with a micropapillary component, commonly
present perineural and lymphovascular invasion and are characterized by abundant
fibrous stroma[97]. On the basis of histological characteristics and in particular for the
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large amount of stroma, PDAC and CCA share many cross-sectional imaging features
both at computed tomography (CT) scans and magnetic resonance imaging (MRI).
CCA appears as a hypodense lesion on non-contrast-enhanced CT scans, and after
contrast media injection in the early arterial phase presents an irregular peripheral
enhancement with only minor enhancement in the center of the tumor, followed by
progressive enhancement in the portal and the delayed phase, with the late phase
accentuated by the presence of fibrous stroma[98,99]. On MRI, CCA usually appears as a
hypo to isointense lesion on T1-weighted MR images and variably hyperintense in T2-
weighted images[100]. On CT-scan PDAC behaves like a hypoattenuating mass that
shows  less  or  no  enhancement  compared  to  the  normal  peripheral  pancreatic
parenchyma.  On MRI it  appears  as  a  hypointense  lesion on T1-weighted with a
variable appearance on T2 weighted MRI images[101,102]. New advanced endoscopic
techniques such as peroral cholangioscopy and pancreatoscopy are encouraging in
order  to  better  identify  p/dCCA  and  PDAC,  their  diagnostic  role  is  useful  to
differentiate  indeterminate biliary and pancreatic  duct  strictures,  distinguishing
benign and malignant lesions through a bioptic mapping[103,104].
From  an  immunohistochemical  point  of  view,  PDAC  and  p/dCCA  are  both
characterized by mucin overexpression[105]. Notably, while in the healthy pancreatic
ducts  mucins  are  rarely expressed,  their  expression in  biliopancreatic  cancers  is
upregulated,  particularly  that  of  MUC1,  MUC4,  and  MUC5AC[106].  MUC1  in
particular, has been associated with tumor size and high grade of dysplasia. Some
80% of PDAC samples express MUC1[107-109]. Interestingly, an increased expression of
MUC1 in p/dCCA is also reported, particularly, patients with high levels of MUC1
expression carry a significantly worse survival when compared to those with low
MUC1 expression and high MUC2 expression[110]. A correlation between MUC1 and
the presence of metastasis has also been reported in CCA[111].
Regarding MUC4, it is not expressed in normal pancreas, but it has been reported
to be expressed in the earliest PanIN lesions[112]. Furthermore, MUC4 expression has
been associated with the severity of dysplasia, as during carcinogenesis, a gradual
expression  of  MUC4  has  been  demonstrated.  An  association  between  MUC4
expression and PDAC poor prognosis has also been reported[113,114].  In the normal
biliary epithelium, MUC4 is not expressed[115], whereas in CCA, MUC4 expression is
significantly related to worse prognosis, similarly to what is observed in PDAC[116,117].
Moreover, in both biliopancreatic tumors MUC5AC is overexpressed[118-120]  and in
studies  in  which  p/dCCA  and  iCCA  are  distinctly  evaluated,  p/dCCAs  more
frequently express MUC5AC than iCCA[121,122].
The two most commonly mutated genes found in PDAC are Kras and p53. PDAC is
arguably the most Ras-addicted cancer, in fact,  Kras mutations are recognized in
virtually 100% of PDAC cases, from the earliest stages[123-125]. In CCA, Kras mutations
have also been reported, but in a smaller quote of cases compared to the pancreas[126].
Several  studies  revealed  that  Kras  mutations  occur  early  in  BilIN  during  the
cholangiocarcinogenic process[127]. The tumor suppressor gene p53 is also commonly
mutated in both CCA and PDAC and seem to be involved in the latest phases of
tumorigenesis process[128,129]. Regarding the immunophenotype profile, both PDAC
and CCA are characterized by common phenotypic traits such as the expression of
S100P[42,130,131]. Furthermore, they share common tumor markers such as cytokeratin-7,
cytokeratin-17 and cytokeratin-19[132]. In the past decades, with the improvement of
technology many studies aimed to determine the gene-expression profiles of PDAC
using microarray techniques and RNA sequencing[133]. PDAC presents a significant
inter-tumor  and  an  intra-tumor  heterogeneity  and  based  on  patterns  of  gene
expression profiling,  researchers classified PDAC into sub-groups with different
molecular features such as (1) squamous; (2) pancreatic progenitor; (3) immunogenic;
and (4) aberrantly differentiated endocrine exocrine, that reflect a different clinical
behavior with a potential for specific personalized treatment[134-136]. Genomic profiling
studies have highlighted distinct subtypes also regarding CCA[137], some evidences
demonstrated two main classes: the inflammation and the proliferation, with the latter
being associated with worse outcome compared to the inflammation class[138].  In
addition, in the past few years, an increasing attention has been paid on the potential
role of noncoding RNAs (ncRNAs), classified according to their length into long (>
200 nucleotides)  and small  (18  to  200  nucleotides),  for  their  involvement  in  cell
proliferation, growth, tumor progression and drug resistance of several tumors[139,140].
Among  small  noncoding  RNAs,  microRNAs  (miRNAs),  composed  by  18  to  24
nucleotides in length, are the most investigated and they act as master gene regulators
involved in a variety of cellular pathways crucial to regular cellular functions[141,142].
The earliest evidences demonstrated a role of miRNAs in cholangiocarcinogenesis, in
fact, the overexpression of certain miRNAs, for example miR-21, miR-25, miR-26a,
miR-191, and miR-221, is involved in proliferation, tumor growth, migration and
invasion of  CCA[143-147].  Many efforts  have been made to isolate  and characterize
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miRNAs on CCA specimens and body fluids (serum, bile and urine) for their possible
usefulness in clinic as promising diagnostic and prognostic biomarkers[148-152]. MiRNAs
are extensively studied also in pancreatic carcinogenesis; they have been classified in
oncogenic and tumor suppressor miRNAs according to their role in carcinogenic
process. The upregulation of certain miRNAs such as miR-21, miR-196a, miR-221/222,
is involved in mechanisms of cell proliferation, migration, inhibition of apoptosis and
chemoresistance of PDAC, and several evidences showed miRNAs’ potential role as
prognostic and diagnostic biomarkers[153-156]. In addition, in PDAC samples certain
miRNAs acting as tumor suppressor are found to be downregulated, such as miR-126
and let-7 involved in the control of migration and invasion of PDAC[157,158].
These two tumor entities, therefore, share a wide range of common features such as
histological aspects and immunophenotype profiles. These molecular characteristics
could  explain  the  similar  dismal  prognosis  of  both  PDAC  and  CCA,  which  is
substantially due to advanced stage at time of presentation and poor response to
conventional chemotherapy and radiotherapy (Table 1).
CONCLUSION
In  conclusion,  preneoplastic  and  neoplastic  lesions  of  the  biliary  tract  and  the
pancreas  share  similar  histologic,  biologic  and  molecular  characteristics.  These
features are principally due to their anatomical proximity and common embryological
origin. On the basis of these important similarities, it would be relevant to conduct
studies  aimed at  identifying new strategies  to  prevent  and treat  biliopancreatic
neoplastic lesions, considering them as a common disease entity
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Table 1  Main similarities and differences in terms of embryologic origin and molecular characteristics between biliary and pancreatic
neoplastic lesions
Biliary tract Pancreas Ref.
Embryologic origin of the ductal
system
EHBDs and large IHBD from ventral
part of foregut; small IHBD from
Mesenchymal cells surrounding the
septum transversum
Ventral part of MPD from the ventral
part of foregut. Dorsal part of MPD
from the dorsal bud that obliterates
completely; the ducts of the dorsal
bud fuse with the ductal system of
the ventral part
[1-5]
Niches of Stem/progenitors’ cells PBGs located in EHBDs and large
IHBDs. Canals of Hering
PDGs located in MPD and larger
interlobular ducts > 300 μm
[6-12]
Microscopic (intraepithelial)
precursors of cancer
BilIN-1 low grade, BilIN-2
intermediate grade, BilIN-3 high
grade
PanIN low grade, previously -1, -2
PanIN high grade, previously -3
[21-26,29,37-39]
Macroscopic (intraductal)
precursors of cancer
IPNB IPMN
[54-62]
Kras role in cancer Mutated in 15%-30% Mutated in > 90%
[44,123,124,127,129]
p53 role in cancer Mutated in 35%-60% Mutated 40%-87%
[49,125-129]
SHH role in cancer Overexpressed ~ 50% Overexpressed ~ 70%
[159,160]
Mucin expression in biliopancreatic
cancers
MUC-1+ 45%-70% MUC-4+ 35%-50%
(worse prognosis compared to MUC4
negative) MUC5AC+ 30%-60%
MUC-1 + ~ 80% MUC-4+ 30%-80%
(worse prognosis compared to MUC4
negative) MUC5AC+ 10%-70%
[106-122]
S100P expression upregulated in ~75% upregulated in ~ 90%
[42,43,130,131]
EHBDs: Extrahepatic bile ducts; IHBDs: Intrahepatic bile ducts; MPD: Main pancreatic duct; PBGs: Peribiliary glands; PDGs: Pancreatic ductal glands;
BilIN: Biliary intraepithelial neoplasm; PanIN: Pancreatic intraepithelial neoplasm; IPNB: Intraductal papillary neoplasm of the biliary tract; IPMN:
Intraductal papillary mucinous neoplasm of the pancreas.
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